Luisa M Stamm, MD, PhD, further discusses MK-8527 and islatravir-based regimens in HIV research.
Luisa M Stamm, MD, PhD
Advertisement
Associate Vice President of Infectious Disease Clinical Research and Section Head for HIV at Merck.
Articles by Luisa M Stamm, MD, PhD
At IAS 2025, Luisa Stamm, MD, PhD, explains the NRTTI’s mechanism, study setup, and key data on HIV prevention efforts.
Advertisement
Latest Updated Articles
Merck’s MK-8527 Advances to Phase 3 for Once-Monthly HIV PreventionPublished: July 15th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
2
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
3
Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?
4
As NDM-CRE Infections Rise Significantly, Diagnostic Access Emerges as Weak Link
5
